Natural product-derived therapy for glucose homeostasis and TIIDM: Fisetin, isolated from Acacia greggii, Acacia Berlanderi, and Butea among others, inhibits Amysin expression, increases insulin secretion, and decreases the risk of hyperglycemia via down regulation of its target gene Sox4, 18/February/2017, 10.57 pm

Natural product-based therapy for Metastatic cancers: (6)-gingerol (6G), one of the main components of Ginger, increases the expression of TPM1 and inhibits migration, invasion and metastasis of cancer cells via down regulation of its target gene, 18/February/2017, 10.20 am
February 18, 2017
Natural product-derived Anti-AXL therapeutics for enhancing the efficacy of chemotherapies: Combination of Luteolin and Maslinic acid, found in Salvia Tomentsa and Olive oil, respectively, decreases the expression of the AXL receptor and its activating ligand, GAS6, increases the expression of a number of tumor suppressor genes, increases therapeutic index of anticancer drugs, suppresses tumorigenesis, migration, invasion, and metastasis via up regulation of its target gene, 18/January/2017, 11.35 pm
February 18, 2017
Show all

Introduction: What they say

Nobel laureate in Physiology/Medicine (1975) Prof. David Baltimore and his research team, from California Institute of Technology, California, USA, had reported in the September 14, 2014 issue of the Journal “Journal of Experimental Medicine (JEM)” that: “The microRNA-212/132 cluster regulates B cell development by targeting Sox4.”

Subsequently, Prof. Rorsman’s research team, from Oxford Centre for Diabetes, Endocrinology & Metabolism, Radcliffe Department of Medicine, Oxford, U.K; Department of Neuroscience and Physiology, University of Göteborg, Göteborg, Sweden Oxford; and National Institute of Health Research, Biomedical Research Centre, Churchill Hospital, Oxford, U.K, had reported in the March 18, 2016 issue of the Journal “Diabetes” that Increased Expression of the Diabetes Gene SOX4 Reduces Insulin Secretion by Impaired Fusion Pore Expansion.”


What we say:

On the foundation of these interesting findings, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-derived therapy for glucose homeostasis and TIIDM: Fisetin, isolated from Acacia greggii, Acacia Berlanderi, and Butea among others, inhibits Amysin expression, increases insulin secretion, and decreases the risk of hyperglycemia via down regulation of its target gene Sox4.


From Significance of the study to Public health relevance:

Given that: (1) more than 387 million people worldwide are affected by Diabetes mellitus (DM); (2) Diabetes is going to be one of the top 10 causes of death by 2030; (3) the life-long painful injection/drug treatment is required to treat DM; (3) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult ß-cells that were lost in DM; (ii) a cheaper alternative to the existing expensive weight-loss drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, diabetes.


From what is known to what we infer from what they say:

Prof. Rorsman’s research team has recently shown that overexpression of Sox4 results in: (1) increased expression of Amysin; (2) reduction in fusion pore size; (3) impairment of granule emptying; (4) impairment of insulin exit; (5) prevention of hormone release; and (6) reduction of glucose-induced insulin secretion, suggesting that decreasing the expression of Sox4 and its target gene Amysin in diabetic patients may alleviate TIIDM.


From Research findings to Therapeutic opportunity:

Fiesetin inhibits Sox4 and amysin expression

Figure 1. Mechanistic insight into how Fisetin promotes insulin sensitivity. Fisetin decreases Sox4 and its target gene Amysin and promotes insulin secretion

Fisetin, by increasing the expression of its target genes, it may decrease the expression of Sox4 (fig.1).price-300

Thereby, it may: (1) decrease the expression of exocytosis-regulating protein Amysin; (2) promote granule emptying and insulin release; and (3) increase glucose-induced-insulin secretion (Fig.1). Thus, pharmacological formulations encompassing “Fisetin or its analogues either alone or in combination with other drugs” may be used to treat TIIDM.


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Fisetin decrease the expression of SOX4 and its target gene Amysin to increase insulin secretion?

Amount: $300

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org

# Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com/

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Citation: Boominathan, L., Natural product-derived therapy for glucose homeostasis and TIIDM: Fisetin, isolated from Acacia greggii, Acacia Berlanderi, and Butea among others, inhibits Amysin expression, increases insulin secretion, and decreases the risk of hyperglycemia via down regulation of its target gene Sox4,  18/February/2017, 10.57 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Comments are closed.